divislab glp-1 novo nordisk relation A $60 billion industry just found its next growth lever. 💊 With the expiry of a key patent on March 20, 2026, Indian pharma majors are launching generic weight-loss and diabetes drugs Novo Nordisk promotes new GLP-1

503702, BioLegend) diluted in coating buffer, washed and blocked for 2 h at room temperature

(PubMed) Kuo YM, Hayflick SJ, Gitschier J

Valproic Acid Trough Levels by Visit

Clinical Evidence for Phentermine Topiramate in Obesity Treatment The clinical evidence base for phentermine topiramate derives predominantly from trials conducted in the United States, with the pivotal CONQUER and EQUIP studies forming the cornerstone of regulatory submissions

Department of Health and Human Services, Office of Inspector General

Numerous HIF stabilizers have been studied in a number of clinical trials, including enarodustat, molidustat, desidustat, vadadustat, roxadustat, and daprodustat (252)